Aldevron has expanded its leadership team by appointing Michelle Berg President of its GMP nucleic acids business unit. She will report to Michael Chambers, Aldevron’s founder and CEO.
James Brown, Ph.D., presenting "Standardized Plasmids for Viral Vector Production" tech talk at American Society of Gene & Cell Therapy Annual Meeting
Representatives from Aldevron will attend the 22nd Annual Meeting for the American Society of Gene & Cell Therapy (ASGCT), April 29 - May 2, 2019, in Washington, D.C.
Novel Packaging and Expression Plasmids Promise to Reduce Gene Therapy Manufacturing Costs and Delivery Times
Miami, FL - Aldevron announced from Phacilitate Leaders World in Miami the immediate availability of standardized plasmids for lentiviral production through a license agreement with Oxford Genetics.
Aldevron has selected AES Clean Technology, a leader in the design, manufacturing, and construction of modular cleanroom systems, to design modular cleanrooms for Aldevron’s $30 million, 70,000 square-foot manufacturing facility in Fargo, N.D. Cleanroom construction is underway with target completion date of early summer.
New plasmid to reduce cost and timeline for gene therapy manufacturing
Aldevron, the world’s leading contract plasmid manufacturing organization, has announced the immediate availability of an off-the-shelf version of pXX6-80, a common adeno-associated virus (AAV) helper plasmid. The plasmid is designed to reduce the cost of AAV manufacturing and subsequent gene therapy applications, while helping Aldevron’s clients meet regulatory requirements.